Switching

Switching From Mounjaro to Zepbound: Same Drug, New Label

GLP-1 Companion · 7 min read

If your doctor is suggesting you move from Mounjaro to Zepbound, or if you are researching whether this switch makes sense, the first thing to understand is that these two medications are pharmaceutically identical. Both contain tirzepatide, the same active ingredient at the same doses, manufactured by Eli Lilly. The pens look similar, the injection process is the same, and the pharmacology is entirely the same. What differs is the FDA-approved indication — and that difference has significant downstream effects on insurance coverage, prior authorizations, and out-of-pocket costs.

The Same Molecule, Two Labels

Tirzepatide was first approved by the FDA as Mounjaro in May 2022 for the treatment of type 2 diabetes. Following the SURMOUNT clinical program, which demonstrated dramatic weight loss outcomes, tirzepatide was approved under the brand name Zepbound in November 2023 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Eli Lilly chose a separate brand name to facilitate distinct commercial and insurance positioning for the obesity indication. Clinically, however, the product is identical: the same peptide, the same doses (2.5 mg through 15 mg), the same injection pens, and the same once-weekly subcutaneous administration.

Why the Switch Is Made

There are two primary scenarios that lead to a Mounjaro-to-Zepbound switch.

• The patient does not have type 2 diabetes: Mounjaro is approved for T2D management. If a patient was using Mounjaro off-label for weight loss — which was common during the period before Zepbound's approval — their insurer may now require them to switch to Zepbound, which holds the obesity indication.
• Better insurance coverage under the obesity indication: Many commercial plans and, starting in 2025, certain Medicare Part D plans cover Zepbound for obesity under specific criteria, while coverage of Mounjaro may be contingent on a diabetes diagnosis. For patients without T2D, Zepbound is more likely to be covered.
• Provider preference and documentation alignment: Prescribers often prefer to align the prescription with the medication's approved indication for cleaner prior authorization submissions and reduced audit risk.

No Clinical Difference to Expect

Patients switching from Mounjaro to Zepbound at the same dose should notice absolutely no change in how they feel, how their appetite responds, how their blood sugar is managed, or how their weight trends. The injection pens are nearly identical in design, and the injection technique is the same. The only observable difference for most patients is the branding on the packaging and potentially their copay amount.

Insurance Coverage and Prior Auth for Zepbound

Despite the clinical equivalence, the insurance re-authorization process is not automatic. Switching from Mounjaro (diabetes indication) to Zepbound (obesity indication) triggers a new prior authorization review, and the documentation requirements are different.

• For Zepbound approval, insurers typically require documentation of BMI of 30 or greater, or BMI of 27 or greater with a qualifying comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.
• Many plans require documentation of a prior lifestyle intervention (usually three to six months of structured diet and exercise counseling) before approving Zepbound.
• Some plans include a step therapy requirement, meaning they require evidence that the patient tried and did not succeed with certain other interventions first.
• Processing a prior authorization typically takes one to three weeks. Starting the process before your current Mounjaro supply runs out prevents a coverage gap.
• If coverage is denied, your provider can request a peer-to-peer review or submit an appeal with additional clinical documentation.

Cost Comparison

The list prices for Mounjaro and Zepbound are similar — both exceed $1,000 per month without insurance. Out-of-pocket costs diverge based on your insurance plan and the applicable savings programs. Eli Lilly's Zepbound savings card offers eligible commercially insured patients costs as low as $25 to $550 per month depending on their plan. Mounjaro has a comparable savings program for commercially insured patients with type 2 diabetes. For uninsured patients, Lilly's direct-to-consumer vial program for Zepbound (introduced in 2024) offered lower-cost options at approximately $399 to $549 per month depending on dose, providing an alternative to compounded versions.

Medicare and Medicaid Considerations

Medicare coverage for obesity medications has been a contentious policy area. The Inflation Reduction Act and subsequent CMS negotiations affected GLP-1 pricing, and some Medicare Part D plans added Zepbound coverage starting in 2025 under specific circumstances. However, manufacturer savings cards and discount programs do not apply to Medicare or Medicaid beneficiaries. Patients in these programs should work directly with their plan and provider to understand the specific coverage criteria and available assistance programs.

Re-Submitting Your Prior Authorization

When your provider submits the Zepbound prior authorization, they will need your current BMI measurement, documentation of any qualifying comorbidities, a record of prior lifestyle intervention if required by your plan, and a clinical justification for the switch. If you have already been on tirzepatide via Mounjaro, your prescriber can note your documented response and tolerance, which strengthens the case. Provide your insurer and provider with your most recent measurements and any relevant lab results to support the submission.

1. Confirm your BMI and qualifying comorbidities are documented in your medical record within the last 12 months.
2. Ask your provider to note your tirzepatide treatment history and outcomes in the prior auth letter.
3. Contact your insurer's member services to confirm what documentation is required for Zepbound approval.
4. Request the prior authorization at least two to three weeks before your Mounjaro supply ends.
5. If your plan requires step therapy, ask your provider to document prior treatment history that satisfies this requirement.
6. Confirm your preferred pharmacy has Zepbound in stock at your dose before the authorization is finalized.

The Mounjaro-to-Zepbound switch is one of the few medication transitions where the clinical question is essentially settled — the drug is the same — and the entire challenge is administrative.

Key Takeaways

Mounjaro and Zepbound are clinically identical products. Switching between them involves no dose adjustment, no restart, and no expected change in efficacy or side effects. The entire process is about aligning the prescription with the appropriate indication to optimize insurance coverage. For patients without type 2 diabetes, Zepbound is typically the correct medication to have prescribed. Initiate the prior authorization well in advance, document your clinical profile thoroughly, and work with your provider to present the strongest possible case to your insurer.

Sources

• Mounjaro (tirzepatide) Prescribing Information. Eli Lilly.
• Zepbound (tirzepatide) Prescribing Information. Eli Lilly.